Evidence map›Paper›PMID 39119292›Full record

ArticleFrontiers in cellular and infection microbiology2024

Oxysterole-binding protein targeted by SARS-CoV-2 viral proteins regulates coronavirus replication.

Yue Ma-Lauer, Pengyuan Li, Daniela Niemeyer, Anja Richter, Konstantin Pusl, Brigitte von Brunn, Yi Ru, Chengyu Xiang, Sebastian Schwinghammer, Jia Liu and 9 more

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yue Ma-Lauer *Virology Department, Max-von-Pettenkofer Institute, Ludwig-Maximilians-University Munich, Munich, Germany.
Pengyuan Li *Virology Department, Max-von-Pettenkofer Institute, Ludwig-Maximilians-University Munich, Munich, Germany.
Daniela NiemeyerInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Anja RichterInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Konstantin PuslVirology Department, Max-von-Pettenkofer Institute, Ludwig-Maximilians-University Munich, Munich, Germany.
Brigitte von BrunnVirology Department, Max-von-Pettenkofer Institute, Ludwig-Maximilians-University Munich, Munich, Germany.
Yi RuVirology Department, Max-von-Pettenkofer Institute, Ludwig-Maximilians-University Munich, Munich, Germany.
Chengyu XiangVirology Department, Max-von-Pettenkofer Institute, Ludwig-Maximilians-University Munich, Munich, Germany.
Sebastian SchwinghammerVirology Department, Max-von-Pettenkofer Institute, Ludwig-Maximilians-University Munich, Munich, Germany.
Jia LiuVirology Department, Max-von-Pettenkofer Institute, Ludwig-Maximilians-University Munich, Munich, Germany.
Priya BaralVirology Department, Max-von-Pettenkofer Institute, Ludwig-Maximilians-University Munich, Munich, Germany.
Emilia J BertholdVirology Department, Max-von-Pettenkofer Institute, Ludwig-Maximilians-University Munich, Munich, Germany.
Haibo QiuDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, The University of Iowa, Iowa City, IA, United States.
Avishek RoyDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, The University of Iowa, Iowa City, IA, United States.
Elisabeth KremmerBioSysM, Ludwig-Maximilians-University Munich, Munich, Germany.
Heinrich FlaswinkelBioSysM, Ludwig-Maximilians-University Munich, Munich, Germany.
Christian DrostenInstitute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Zhendong JinDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, The University of Iowa, Iowa City, IA, United States.
Albrecht von BrunnVirology Department, Max-von-Pettenkofer Institute, Ludwig-Maximilians-University Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Oxysterol-binding protein (OSBP) is known for its crucial role in lipid transport, facilitating cholesterol exchange between the Golgi apparatus and endoplasmic reticulum membranes. Despite its established function in cellular processes, its involvement in coronavirus replication remains unclear. Methods: In this study, we investigated the role of OSBP in coronavirus replication and explored the potential of a novel OSBP-binding compound, ZJ-1, as an antiviral agent against coronaviruses, including SARS-CoV-2. We utilized a combination of biochemical and cellular assays to elucidate the interactions between OSBP and SARS-CoV-2 non-structural proteins (Nsps) and other viral proteins. Results: Our findings demonstrate that OSBP positively regulates coronavirus replication. Moreover, treatment with ZJ-1 resulted in reduced OSBP levels and exhibited potent antiviral effects against multiple coronaviruses. Through our investigation, we identified specific interactions between OSBP and SARS-CoV-2 Nsps, particularly Nsp3, Nsp4, and Nsp6, which are involved in double-membrane vesicle formation-a crucial step in viral replication. Additionally, we observed that Nsp3 a.a.1-1363, Nsp4, and Nsp6 target vesicle-associated membrane protein (VAMP)-associated protein B (VAP-B), which anchors OSBP to the ER membrane. Interestingly, the interaction between OSBP and VAP-B is disrupted by Nsp3 a.a.1-1363 and partially impaired by Nsp6. Furthermore, we identified SARS-CoV-2 orf7a, orf7b, and orf3a as additional OSBP targets, with OSBP contributing to their stabilization. Conclusion: Our study highlights the significance of OSBP in coronavirus replication and identifies it as a promising target for the development of antiviral therapies against SARS-CoV-2 and other coronaviruses. These findings underscore the potential of OSBP-targeted interventions in combating coronavirus infections.

Indexed as

Antiviral AgentsReceptors, SteroidSARS-CoV-2Viral Nonstructural ProteinsVirus ReplicationAnimalsChlorocebus aethiopsCoronavirus Papain-Like ProteasesCOVID-19Endoplasmic ReticulumHEK293 CellsHumansOxysterol Binding ProteinsProtein BindingVero CellsViral ProteinsAntiviral AgentsCoronavirus Papain-Like ProteasesORF7a protein, SARS-CoV-2Oxysterol Binding ProteinsReceptors, SteroidViral Nonstructural ProteinsViral ProteinsViroporin ProteinscoronavirusNsp3Nsp4Nsp6OSBPSARS-CoV-2VAP-B

Identifiers

PMID39119292
PMCPMC11306179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.